74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Immunocore Holdings PLC ADR
Closed
35.04 -1.74
Overview
Share price change
24h
Min
34.9
Max
35.69
Income | -15M -10M |
|---|---|
Sales | 4.1M 98M |
Profit margin | -10.514 |
Employees | 493 |
EBITDA | -11M -15M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +64.51% upside |
Next Earnings | 4 Nov 2025 |
|---|
Market Cap | 96M 1.7B |
|---|---|
Previous open | 36.78 |
Previous close | 35.04 |
Technical Score
By Trading Central
Confidence
Weak Bearish Evidence
Immunocore Holdings PLC ADR Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Immunocore Holdings PLC ADR Forecast
Price Target
By TipRanks
64.51% upside
12 Months Forecast
Average 59.11 USD 64.51%
High 100 USD
Low 34 USD
Based on 10 Wall Street analysts offering 12 month price targets forImmunocore Holdings PLC ADR - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Immunocore Holdings PLC ADR
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Live chat